Aldose Reductase, Oxidative Stress and Diabetic Cardiovascular Complications

Overview

Journal Cardiovasc Hematol Agents Med Chem

Publisher Bentham Science Publishers

Specialties Cardiology & Vascular Diseases
Chemistry
Hematology
Pharmacology

Date 2012 May 29

PMID 22632267

Citations 18

Authors

Srinivasan Vedantham

Radha Ananthakrishnan

Ann Marie Schmidt

Ravichandran Ramasamy

Affiliations

Soon will be listed here.

Abstract

Cardiovascular disease represents the major cause of morbidity and mortality in patients with diabetes mellitus. Studies by us and others have implicated increased flux via aldose reductase (AR) as a key player in mediating diabetic complications, including cardiovascular complications. Data suggest that increased flux via AR in diabetics perpetuates increased injury after myocardial infarction, accelerates atherosclerotic lesion formation, and promotes restenosis via multiple mechanisms. Most importantly, studies have shown that increased generation of reactive oxygen species due to flux via AR has been a common feature in animal models of diabetic cardiovascular disease. Taken together, these considerations place AR in the center of biochemical and molecular stresses that characterize the cardiovascular complications of diabetes. Stopping AR-dependent signaling may hold the key to interrupting cycles of cellular perturbation and tissue damage in diabetic cardiovascular complications.

Citing Articles

Diabetic Cardiomyopathy: Pathophysiology and Novel Therapies.

Laksono S, Hosea G, Nurusshofa Z Brown J Hosp Med. 2025; 1(3):37850.

PMID: 40046584 PMC: 11878873. DOI: 10.56305/001c.37850.

The aldose reductase inhibitors AT-001, AT-003 and AT-007 attenuate human keratinocyte senescence.

Yepuri G, Kancharla K, Perfetti R, Shendelman S, Wasmuth A, Ramasamy R Front Aging. 2025; 5:1466281.

PMID: 39741583 PMC: 11685203. DOI: 10.3389/fragi.2024.1466281.

Exploring potent aldose reductase inhibitors for anti-diabetic (anti-hyperglycemic) therapy: integrating structure-based drug design, and MMGBSA approaches.

Shahab M, Zheng G, Alshabrmi F, Bourhia M, Wondmie G, Salamatullah A Front Mol Biosci. 2023; 10:1271569.

PMID: 38053577 PMC: 10694256. DOI: 10.3389/fmolb.2023.1271569.

The role of autophagy in the treatment of type II diabetes and its complications: a review.

Zhao X, Bie L, Pang D, Li X, Yang L, Chen D Front Endocrinol (Lausanne). 2023; 14:1228045.

PMID: 37810881 PMC: 10551182. DOI: 10.3389/fendo.2023.1228045.

The role of oxidative stress in diabetes mellitus-induced vascular endothelial dysfunction.

An Y, Xu B, Wan S, Ma X, Long Y, Xu Y Cardiovasc Diabetol. 2023; 22(1):237.

PMID: 37660030 PMC: 10475205. DOI: 10.1186/s12933-023-01965-7.

References

Ido Y, Chang K, Woolsey T, Williamson J . NADH: sensor of blood flow need in brain, muscle, and other tissues. FASEB J. 2001; 15(8):1419-21. DOI: 10.1096/fj.00-0652fje. View

Nishikawa T, Edelstein D, Du X, Yamagishi S, Matsumura T, Kaneda Y . Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000; 404(6779):787-90. DOI: 10.1038/35008121. View

Csiszar A, Ungvari Z, Edwards J, Kaminski P, Wolin M, Koller A . Aging-induced phenotypic changes and oxidative stress impair coronary arteriolar function. Circ Res. 2002; 90(11):1159-66. DOI: 10.1161/01.res.0000020401.61826.ea. View

Tang W, Wu S, Wong T, Chung S, Chung S . Polyol pathway mediates iron-induced oxidative injury in ischemic-reperfused rat heart. Free Radic Biol Med. 2008; 45(5):602-10. DOI: 10.1016/j.freeradbiomed.2008.05.003. View

Didangelos T, Athyros V, Karamitsos D, Papageorgiou A, Kourtoglou G, Kontopoulos A . Effect of aldose reductase inhibition on heart rate variability in patients with severe or moderate diabetic autonomic neuropathy. Clin Drug Investig. 2008; 15(2):111-21. DOI: 10.2165/00044011-199815020-00005. View

Ramasamy R, Oates P, Schaefer S . Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury. Diabetes. 1997; 46(2):292-300. DOI: 10.2337/diab.46.2.292. View

Shinmura K, Bolli R, Liu S, Tang X, Kodani E, Xuan Y . Aldose reductase is an obligatory mediator of the late phase of ischemic preconditioning. Circ Res. 2002; 91(3):240-6. DOI: 10.1161/01.res.0000029970.97247.57. View

Ramana K, Friedrich B, Srivastava S, Bhatnagar A, Srivastava S . Activation of nuclear factor-kappaB by hyperglycemia in vascular smooth muscle cells is regulated by aldose reductase. Diabetes. 2004; 53(11):2910-20. DOI: 10.2337/diabetes.53.11.2910. View

SARGES R, Oates P . Aldose reductase inhibitors: recent developments. Prog Drug Res. 1993; 40:99-161. DOI: 10.1007/978-3-0348-7147-1_5. View

10.

Vikramadithyan R, Hu Y, Noh H, Liang C, Hallam K, Tall A . Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J Clin Invest. 2005; 115(9):2434-43. PMC: 1190371. DOI: 10.1172/JCI24819. View

11.

Ceriello A, Motz E . Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol. 2004; 24(5):816-23. DOI: 10.1161/01.ATV.0000122852.22604.78. View

12.

Koya D, King G . Protein kinase C activation and the development of diabetic complications. Diabetes. 1998; 47(6):859-66. DOI: 10.2337/diabetes.47.6.859. View

13.

Ido Y, Nyengaard J, Chang K, Tilton R, Kilo C, Mylari B . Early neural and vascular dysfunctions in diabetic rats are largely sequelae of increased sorbitol oxidation. Antioxid Redox Signal. 2009; 12(1):39-51. PMC: 2821145. DOI: 10.1089/ars.2009.2502. View

14.

Ido Y . Pyridine nucleotide redox abnormalities in diabetes. Antioxid Redox Signal. 2007; 9(7):931-42. DOI: 10.1089/ars.2007.1630. View

15.

Srivastava S, Chandrasekar B, Bhatnagar A, Prabhu S . Lipid peroxidation-derived aldehydes and oxidative stress in the failing heart: role of aldose reductase. Am J Physiol Heart Circ Physiol. 2002; 283(6):H2612-9. DOI: 10.1152/ajpheart.00592.2002. View

16.

Petrash J, Tarle I, Wilson D, Quiocho F . Aldose reductase catalysis and crystallography. Insights from recent advances in enzyme structure and function. Diabetes. 1994; 43(8):955-9. DOI: 10.2337/diab.43.8.955. View

17.

Johnson B, Nesto R, Pfeifer M, Slater W, Vinik A, Chyun D . Cardiac abnormalities in diabetic patients with neuropathy: effects of aldose reductase inhibitor administration. Diabetes Care. 2004; 27(2):448-54. DOI: 10.2337/diacare.27.2.448. View

18.

Passariello N, Sepe J, Marrazzo G, De Cicco A, Peluso A, Pisano M . Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate in IDDM subjects with nephropathy. Diabetes Care. 1993; 16(5):789-95. DOI: 10.2337/diacare.16.5.789. View

19.

Lee A, Chung S . Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J. 1999; 13(1):23-30. DOI: 10.1096/fasebj.13.1.23. View

20.

Baynes J . Role of oxidative stress in development of complications in diabetes. Diabetes. 1991; 40(4):405-12. DOI: 10.2337/diab.40.4.405. View